• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Proposals for managing patients with thoracic malignancies during COVID-19 pandemic.COVID-19 大流行期间胸内恶性肿瘤患者的管理建议。
Respir Med Res. 2020 Nov;78:100769. doi: 10.1016/j.resmer.2020.100769. Epub 2020 May 24.
2
Surgical care of thoracic malignancies during the COVID-19 pandemic in México: An expert consensus guideline from the Sociedad Mexicana de Oncología (SMeO) and the Sociedad Mexicana de Cirujanos Torácicos Generales (SMCTG).COVID-19 大流行期间墨西哥胸恶性肿瘤的外科治疗：来自墨西哥肿瘤学会（SMeO）和墨西哥胸外科医师学会（SMCTG）的专家共识指南。
Thorac Cancer. 2020 Aug;11(8):2370-2375. doi: 10.1111/1759-7714.13546. Epub 2020 Jul 6.
3
Thoracic cancer surgery during the COVID-19 pandemic: a consensus statement from the Thoracic Domain of the Asian Society for Cardiovascular and Thoracic Surgery.2019冠状病毒病大流行期间的胸科癌症手术：亚洲心血管和胸外科学会胸科领域的共识声明
Asian Cardiovasc Thorac Ann. 2020 Jul;28(6):322-329. doi: 10.1177/0218492320940162. Epub 2020 Jul 1.
4
Expert Opinion on Restoration of Pediatric Pulmonology Services During the SARS-CoV-2 Pandemic.关于在2019冠状病毒病大流行期间恢复儿科肺病学服务的专家意见
Indian Pediatr. 2020 Nov 15;57(11):1055-1059. doi: 10.1007/s13312-020-2035-z. Epub 2020 Sep 16.
5
Anesthesia for Patients Undergoing Anesthesia for Elective Thoracic Surgery During the COVID-19 Pandemic: A Consensus Statement From the Israeli Society of Anesthesiologists.COVID-19 大流行期间择期行胸科手术患者的麻醉：以色列麻醉医师学会的共识声明。
J Cardiothorac Vasc Anesth. 2020 Dec;34(12):3211-3217. doi: 10.1053/j.jvca.2020.07.049. Epub 2020 Jul 21.
6
Hospital organization and thoracic oncological patient management during the coronavirus disease-2019 outbreak: a brief report from a nationwide survey of the Italian Society of Thoracic Surgery.2019冠状病毒病疫情期间的医院组织与胸科肿瘤患者管理：来自意大利胸外科协会全国性调查的简要报告
Interact Cardiovasc Thorac Surg. 2020 Dec 7;31(6):895-899. doi: 10.1093/icvts/ivaa204.
7
COVID-19 Guidance for Triage of Operations for Thoracic Malignancies: A Consensus Statement From Thoracic Surgery Outcomes Research Network.COVID-19 指导下的胸部恶性肿瘤手术分类：胸外科结局研究网络的共识声明。
Ann Thorac Surg. 2020 Aug;110(2):692-696. doi: 10.1016/j.athoracsur.2020.03.005. Epub 2020 Apr 9.
8
[An example of Clinical Investigations Center reorganization during the COVID-19 pandemic French national lockdown].[新冠疫情法国全国封锁期间临床研究中心重组的一个例子]
Therapie. 2021 Jul-Aug;76(4):347-358. doi: 10.1016/j.therap.2021.02.003. Epub 2021 Feb 14.
9
Consensus statement: summary of the Quebec Lung Cancer Network recommendations for prioritizing patients with thoracic cancers in the context of the COVID-19 pandemic.共识声明：魁北克肺癌网络针对 COVID-19 大流行期间胸部癌症患者优先排序的建议摘要。
Curr Oncol. 2020 Jun;27(3):e313-e317. doi: 10.3747/co.27.6685. Epub 2020 Jun 1.
10
Impact of telemedicine adoption on accessibility and time to treatment in patients with thoracic malignancies during the COVID-19 pandemic.新冠疫情期间，采用远程医疗对胸恶性肿瘤患者的可及性和治疗时间的影响。
BMC Cancer. 2021 Oct 11;21(1):1094. doi: 10.1186/s12885-021-08819-z.

引用本文的文献

1
COVID-19 lockdown-related treatment modifications did not impact the outcome of digestive cancers: the Clin-COVIDICA prospective study.COVID-19疫情封锁相关的治疗调整未影响消化道癌症的治疗结果：Clin-COVIDICA前瞻性研究
BMC Cancer. 2025 Mar 5;25(1):398. doi: 10.1186/s12885-025-13787-9.
2
A Comparative Multicenter Cohort Study Evaluating the Long-Term Influence of the Strict Lockdown during the First COVID-19 Wave on Lung Cancer Patients (ARTEMISIA Trial).一项比较性多中心队列研究，评估第一波新冠疫情期间严格封锁对肺癌患者的长期影响（蒿属试验）。
Cancers (Basel). 2023 Dec 6;15(24):5729. doi: 10.3390/cancers15245729.
3
Impact of extended interval dosing of immune checkpoint inhibitors in lung cancer patients during the COVID-19 pandemic.COVID-19 大流行期间，肺癌患者免疫检查点抑制剂延长间隔给药的影响。
Respir Med Res. 2023 Jun;83:101004. doi: 10.1016/j.resmer.2023.101004. Epub 2023 Feb 18.
4
Lung transplantation in the COVID-19 Era: A multi-faceted challenge.新冠疫情时代的肺移植：一项多方面的挑战。
Respir Med Res. 2022 May;81:100866. doi: 10.1016/j.resmer.2021.100866. Epub 2021 Dec 17.
5
[Not Available].[无可用内容]。
Rev Malad Respir Actual. 2021 Sep;13(2):2S280-2S291. doi: 10.1016/S1877-1203(21)00121-X. Epub 2021 Oct 11.
6
Impact of COVID-19 on the management of patients with thoracic cancers in a tertiary referral center.COVID-19 对三级转诊中心胸癌患者管理的影响。
Lung Cancer. 2021 Jul;157:79-84. doi: 10.1016/j.lungcan.2021.05.007. Epub 2021 May 8.
7
Severe acute respiratory syndrome coronavirus 2 vaccination for patients with solid cancer: Review and point of view of a French oncology intergroup (GCO, TNCD, UNICANCER).严重急性呼吸综合征冠状病毒 2 疫苗接种用于实体瘤患者：法国肿瘤学联合组（GCO、TNCD、UNICANCER）的回顾和观点。
Eur J Cancer. 2021 Jun;150:232-239. doi: 10.1016/j.ejca.2021.03.030. Epub 2021 Apr 1.
8
[Not Available].[无可用内容]
Rev Malad Respir Actual. 2020 Dec;12(2):2S378-2S382. doi: 10.1016/S1877-1203(20)30155-5. Epub 2020 Dec 5.
9
Risk factors for Coronavirus Disease 2019 (COVID-19) severity and mortality among solid cancer patients and impact of the disease on anticancer treatment: A French nationwide cohort study (GCO-002 CACOVID-19).实体瘤癌症患者 2019 年冠状病毒病（COVID-19）严重程度和死亡率的危险因素以及该疾病对癌症治疗的影响：一项法国全国性队列研究（GCO-002 CACOVID-19）。
Eur J Cancer. 2020 Dec;141:62-81. doi: 10.1016/j.ejca.2020.09.035. Epub 2020 Oct 8.
10
Maintaining Surgical Treatment of Non-Small Cell Lung Cancer During the COVID-19 Pandemic in Paris.在巴黎 COVID-19 大流行期间维持非小细胞肺癌的外科治疗。
Ann Thorac Surg. 2021 May;111(5):1682-1688. doi: 10.1016/j.athoracsur.2020.08.007. Epub 2020 Oct 8.

本文引用的文献

1
Alternative dosing regimens for atezolizumab: right dose, wrong frequency.阿替利珠单抗的不同剂量方案：剂量正确，频率错误。
Cancer Chemother Pharmacol. 2019 Dec;84(6):1153-1155. doi: 10.1007/s00280-019-03971-7. Epub 2019 Oct 19.
2
Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial.度伐利尤单抗联合铂类依托泊苷与铂类依托泊苷一线治疗广泛期小细胞肺癌（CASPIAN）：一项随机、对照、开放标签、III 期临床试验。
Lancet. 2019 Nov 23;394(10212):1929-1939. doi: 10.1016/S0140-6736(19)32222-6. Epub 2019 Oct 4.
3
Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC.度伐利尤单抗化疗和放疗后用于 III 期非小细胞肺癌的总生存。
N Engl J Med. 2018 Dec 13;379(24):2342-2350. doi: 10.1056/NEJMoa1809697. Epub 2018 Sep 25.
4
Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer.帕博利珠单抗联合化疗治疗转移性非小细胞肺癌。
N Engl J Med. 2018 May 31;378(22):2078-2092. doi: 10.1056/NEJMoa1801005. Epub 2018 Apr 16.
5
Precision Diagnosis and Treatment for Advanced Non-Small-Cell Lung Cancer.晚期非小细胞肺癌的精准诊断与治疗
N Engl J Med. 2017 Aug 31;377(9):849-861. doi: 10.1056/NEJMra1703413.
6
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial.阿特珠单抗对比多西他赛用于既往治疗过的非小细胞肺癌患者（OAK）：一项3期、开放标签、多中心随机对照试验
Lancet. 2017 Jan 21;389(10066):255-265. doi: 10.1016/S0140-6736(16)32517-X. Epub 2016 Dec 13.
7
The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung Cancer.IASLC 肺癌分期项目：对即将发布的（第八版）肺癌 TNM 分类中 TNM 分期分组的修订建议。
J Thorac Oncol. 2016 Jan;11(1):39-51. doi: 10.1016/j.jtho.2015.09.009.
8
Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial.贝伐珠单抗治疗新诊断的胸膜间皮瘤的 Mesothelioma Avastin Cisplatin Pemetrexed 研究（MAPS）：一项随机、对照、开放标签、3 期临床试验。
Lancet. 2016 Apr 2;387(10026):1405-1414. doi: 10.1016/S0140-6736(15)01238-6. Epub 2015 Dec 21.
9
Carboplatin and weekly paclitaxel doublet chemotherapy compared with monotherapy in elderly patients with advanced non-small-cell lung cancer: IFCT-0501 randomised, phase 3 trial.卡铂和每周紫杉醇联合化疗与单药治疗老年晚期非小细胞肺癌的比较：IFCT-0501 随机、3 期试验。
Lancet. 2011 Sep 17;378(9796):1079-88. doi: 10.1016/S0140-6736(11)60780-0. Epub 2011 Aug 8.

COVID-19 大流行期间胸内恶性肿瘤患者的管理建议。

Proposals for managing patients with thoracic malignancies during COVID-19 pandemic.

机构信息

Department of Medical Oncology, Institut Curie, 75005 Paris, France.

Aix-Marseille Université, AP-HM, INSERM, CNRS, CRCM, Hôpital Nord, Multidisciplinary Oncology and Therapeutic Innovations Department, 13915 Marseille, France.

出版信息

Respir Med Res. 2020 Nov;78:100769. doi: 10.1016/j.resmer.2020.100769. Epub 2020 May 24.

DOI:10.1016/j.resmer.2020.100769
PMID:32563968
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7246014/
Abstract

The objective of this document is to formalize a degraded mode management for patients with thoracic cancers in the context of the COVID-19 pandemic. The proposals are based on those of the French High Council for Public Health, on published data outside the context of COVID-19, and on a concerted analysis of the risk-benefit ratio for our patients by a panel of experts specialized on thoracic oncology under the aegis of the French-Language Society of Pulmonology (SPLF)/French-language oncology group. These proposals are evolving (10 April 2020) according to the situations encountered, which will enrich it, and are to be adapted to our institutional organisations and to the evolution of resources during the COVID-19 epidemic. Patients with symptoms and/or COVID-19+ are not discussed in this document and are managed within the framework of specific channels.

摘要

本文件的目的是在 COVID-19 大流行背景下为胸部癌症患者制定降阶治疗管理模式。这些建议基于法国公共卫生高级理事会的建议、COVID-19 以外的已发表数据，以及胸部肿瘤学专家小组在法国肺病学会（SPLF）/法语肿瘤学组的支持下对我们患者的风险效益比进行的协同分析。这些建议根据所遇到的情况在不断发展（2020 年 4 月 10 日），并将不断丰富这些建议，同时根据 COVID-19 流行期间我们机构的组织和资源的变化进行调整。本文件未讨论有症状和/或 COVID-19+的患者，这些患者在特定渠道内进行管理。